CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial.

TitleCA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial.
Publication TypeJournal Article
Year of Publication2012
AuthorsAlexandre, J, Brown, C, Coeffic, D, Raban, N, Pfisterer, J, Maenpaa, JU, Chalchal, H, Fitzharris, B, Volgger, B, Vergote, IB, Pisano, C, Ferrero, A, Pujade-Lauraine, E
JournalBr J Cancer
Volume106
Start Page633
Issue4
Pagination637
Date Published02/2012
ISSN1532-1827
KeywordsAntineoplastic Combined Chemotherapy Protocols, CA-125 Antigen, Carboplatin, Disease Progression, Disease-Free Survival, Doxorubicin, Female, Humans, Ovarian Neoplasms, Paclitaxel, Polyethylene Glycols, Recurrence, Tomography, X-Ray Computed
Abstract

BACKGROUND: CA-125 as a tumour progression criterion in relapsing ovarian cancer (ROC) trials remains controversial. CALYPSO is a large randomised trial incorporating CA-125 (GCIG criteria) and symptomatic deterioration in addition to Response Evaluation Criteria in Solid Tumours (RECIST) criteria (radiological) to determine progression.METHODS: In all, 976 patients with platinum-sensitive ROC were randomised to carboplatin-paclitaxel (C-P) or carboplatin-pegylated liposomal doxorubicin (C-PLD). CT-scan and CA-125 were performed every 3 months until progression.RESULTS: In all, 832 patients (85%) progressed, with 60% experiencing a first radiological progression, 10% symptomatic progression, and 28% CA-125 progression without evidence of radiological or symptomatic progression. The benefit of C-PLD vs C-P in progression-free survival was not influenced by type of first progression (hazard ratio 0.85 (95% confidence interval (CI): 0.66-1.10) and 0.84 (95% CI: 0.72-0.98) for CA-125 and RECIST, respectively). In patients with CA-125 first progression who subsequently progressed radiologically, a delay of 2.3 months was observed between the two progression types. After CA-125 first progression, median time to new treatment was 2.0 months. In all, 81%of the patients with CA-125 or radiological first progression and 60% with symptomatic first progression received subsequent treatment.CONCLUSION: CA-125 and radiological tests performed similarly in determining progression with C-PLD or C-P. Additional follow-up with CA-125 measurements was not associated with overtreatment.

DOI10.1038/bjc.2011.593
Alternate JournalBr. J. Cancer
PubMed ID22240800
PubMed Central IDPMC3322951